Last week, uniQure achieved a breakthrough in developing disease-modifying therapies for Huntington’s Disease by showing that AMT-130 slowed disease progression by 75%. AMT-130 is a DNA-directed RNAi construct targeting a sequence in the triplett-expanded exon 1 of the 67 exons-containing huntingtin gene. Since other approaches aimed at lowering full-length huntingti...
follow.it gives you an easy way to subscribe to Rnaitherapeutics's news feed! Click on Follow below and we deliver the updates you want via email, phone or you can read them here on the website on your own news page.
You can also unsubscribe anytime painlessly. You can even combine feeds from Rnaitherapeutics with other site's feeds!
Title: RNAi Therapeutics